Pluristem Submits FDA Orphan Drug Application for Preeclampsia
Pluristem Therapeutics, Inc., a leading developer of placenta-based cell therapies, today announced it is submitting its application to the United Stated Food and Drug Administration requesting the Company to be granted Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells in the treatment of severe preeclampsia.
View full press release